DBV Technologies (NASDAQ:DBVT) Stock Price Passes Above 50 Day Moving Average – What’s Next?

DBV Technologies S.A. (NASDAQ:DBVT)’s share price crossed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $18.47 and traded as high as $23.53. DBV Technologies shares last traded at $21.61, with a volume of 395,621 shares.

Analyst Ratings Changes

Several equities analysts have issued reports on DBVT shares. Cantor Fitzgerald set a $48.00 price objective on shares of DBV Technologies in a research note on Wednesday, December 17th. HC Wainwright set a $40.00 price objective on DBV Technologies in a report on Thursday, December 18th. Guggenheim reaffirmed a “buy” rating and set a $51.00 price objective (up previously from $35.00) on shares of DBV Technologies in a report on Wednesday, December 17th. Citigroup restated an “outperform” rating on shares of DBV Technologies in a research report on Wednesday, December 17th. Finally, Citizens Jmp increased their target price on shares of DBV Technologies from $21.00 to $45.00 and gave the company a “market outperform” rating in a report on Wednesday, December 17th. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, DBV Technologies has a consensus rating of “Moderate Buy” and a consensus price target of $35.38.

DBV Technologies Stock Performance

The firm has a fifty day moving average of $18.47 and a 200 day moving average of $13.96. The firm has a market capitalization of $867.86 million, a PE ratio of -4.18 and a beta of -1.17.

Insider Buying and Selling at DBV Technologies

In related news, major shareholder Bpifrance Epic sold 2,076,990 shares of the firm’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $4.85, for a total transaction of $10,073,401.50. Following the completion of the sale, the insider directly owned 8,595,472 shares of the company’s stock, valued at approximately $41,688,039.20. This trade represents a 19.46% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.44% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC increased its holdings in shares of DBV Technologies by 38.4% in the 4th quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock valued at $51,000 after acquiring an additional 744 shares during the last quarter. New York State Common Retirement Fund bought a new position in DBV Technologies during the 3rd quarter worth $34,000. Two Sigma Investments LP acquired a new stake in DBV Technologies in the third quarter worth $167,000. Citadel Advisors LLC bought a new stake in DBV Technologies in the third quarter valued at $220,000. Finally, DLD Asset Management LP bought a new stake in DBV Technologies in the third quarter valued at $250,000. 71.74% of the stock is currently owned by institutional investors.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.